Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when HQY files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsHealthEquity terminates Chief Commercial Officer Michael Fiore without cause
Filed October 9, 2026 · Period ending October 5, 2026 · ~1 min read
Key Changes
-
high
HealthEquity terminated Chief Commercial Officer Michael Fiore without cause, effective October 5, 2026.
Item 5.02 verify on EDGAR → -
medium
Fiore will receive previously negotiated severance payments and benefits under his employment agreement, contingent on a release of claims and restrictive covenants.
Item 5.02 verify on EDGAR → -
medium
His outstanding equity awards will be treated under the 2014 and 2024 Stock Incentive Plans and applicable award agreements.
Item 5.02 verify on EDGAR → -
medium
The company did not name a successor; Fiore's responsibilities will be redistributed to other management team members.
Item 5.02 verify on EDGAR →
Summary
HealthEquity disclosed in an 8-K filed October 9, 2026, that it terminated Chief Commercial Officer Michael Fiore without cause, effective October 5, 2026. The filing states his responsibilities will be redistributed to other members of the management team, and no successor was named. Fiore will receive the severance payments and benefits previously negotiated in his employment agreement, as detailed in the company's most recent proxy statement, contingent on signing a release of claims and complying with restrictive covenants.
His outstanding equity awards will be treated in accordance with the 2014 and 2024 Stock Incentive Plans and his award agreements. The filing does not disclose the dollar amount of the severance. This is a routine executive departure disclosure with no red flags.
Section-by-Section Diff
Event · Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation
Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
Mr. Fiore will receive the previously negotiated severance payments and benefits set forth in his employment agreement, as detailed in the Company’s most recent proxy statement filed with the Securities and Exchange Commission on May 13, 2026, and his outstanding equity awards will be treated in a manner consistent with the terms of the 2014 Stock Incentive Plan, the 2024 Stock Incentive Plan, and his applicable award agreements, each as previously filed.
Fiore will receive the severance payments and benefits already negotiated in his employment agreement, contingent on signing a release of claims and complying with restrictive covenants. His outstanding equity awards will be handled under the existing stock incentive plans and award agreements. The filing does not disclose the dollar amount of the severance.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Oct 12, 2026 · How we verify